These data suggest that combining IFNα and PD-1/PD-L1 blockade therapy coordinately induces a robust tumor-specific T-cell response that can overcome tumor resistance to checkpoint blockade in advanced tumors. The gene discussed is CD274; the disease is neoplasm.